[{"id":"acc48af8-087d-49b6-a58a-47451b735f6f","acronym":"COMBIGaPP","url":"https://clinicaltrials.gov/study/NCT06782022","created_at":"2025-02-25T20:11:02.556Z","updated_at":"2025-02-25T20:11:02.556Z","phase":"Phase 2","brief_title":"DPD Guided 5-FU Precision Treatment in Gastro-intestinal Cancer Patients","source_id_and_acronym":"NCT06782022 - COMBIGaPP","lead_sponsor":"Jan Gerard Maring","biomarkers":" DPYD","pipe":"","alterations":" ","tags":["DPYD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 02/02/2020","start_date":" 02/02/2020","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2025-01-17"},{"id":"98588e49-2647-4d0a-b2de-48312785bbd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05266300","created_at":"2022-03-04T16:53:39.437Z","updated_at":"2024-07-02T16:36:01.497Z","phase":"","brief_title":"Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.","source_id_and_acronym":"NCT05266300","lead_sponsor":"University of Southern Denmark","biomarkers":" DPYD","pipe":"","alterations":" ","tags":["DPYD"],"overall_status":"Completed","enrollment":" Enrollment 722","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-11-01"},{"id":"ee12b221-9576-4717-8bca-d54f5b047a80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04269369","created_at":"2021-01-18T20:44:35.934Z","updated_at":"2024-07-02T16:36:50.035Z","phase":"Phase 4","brief_title":"Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients","source_id_and_acronym":"NCT04269369","lead_sponsor":"Jessa Hospital","biomarkers":" DPYD","pipe":" | ","alterations":" DPYD wild-type","tags":["DPYD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DPYD wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine"],"overall_status":"Unknown status","enrollment":" Enrollment 250","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2020-02-13"},{"id":"3aba74d5-7b76-4c3f-848e-0823c6e0059e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00478686","created_at":"2021-01-18T01:42:34.032Z","updated_at":"2024-07-02T16:37:22.768Z","phase":"","brief_title":"Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine","source_id_and_acronym":"NCT00478686","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" DPYD","pipe":"","alterations":" ","tags":["DPYD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 05/23/2007","start_date":" 05/23/2007","primary_txt":" Primary completion: 05/02/2017","primary_completion_date":" 05/02/2017","study_txt":" Completion: 05/02/2017","study_completion_date":" 05/02/2017","last_update_posted":"2017-05-08"}]